ASCO 2023 | Personalized treatment approaches for patients with KRAS-mutant pancreatic cancer

Bach Ardalan, MD, University of Miami, Coral Gables, FL, describes the utility of stratifying patients with KRAS-mutant pancreatic cancer based on the mutation. Those with KRAS G12R mutations tend to have worse outcomes when treated with chemotherapy compared to patients with G12D and G12V mutations. Tailoring the treatment to specific subtypes will, thus, increase survival rates in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.